IPM Take
ASCO is full of drugs, but the hidden access layer is diagnostics. RAS inhibitors, ADCs, ctDNA-guided therapy, HRD-directed treatment and rare cancer matching all depend on whether profiling systems work. Genomic testing is no longer a laboratory side issue. It is the machinery that turns scientific eligibility into a treatment route.
Executive Summary
Foundation Medicine announced 14 abstracts at ASCO 2026 across its comprehensive genomic profiling portfolio. The company’s ASCO research package included copy-number loss detection, serial circulating tumour DNA genomic profiling, homologous recombination deficiency signatures, molecular tumour board approaches and additional work on profiling in advanced and rare cancers. The direct announcement framed the work around clinical utility, therapy selection and precision oncology research infrastructure.
Why it matters
- Diagnostics / pathology: Need scalable, high-quality profiling and reporting systems that fit real clinical timelines.
- Payers / HTA bodies: Must decide how to fund tests that unlock multiple treatment pathways, not one single therapy.
- Clinicians: Molecular results have to arrive early enough to change the treatment decision.
A patient cannot benefit from a biomarker-defined therapy if the biomarker is never found. This sounds obvious. In practice, it is still one of the main failure points in precision oncology.
The ASCO 2026 profiling package is important because it sits behind many of the meeting’s headline drug stories. RAS-targeted therapy needs molecular identification. ADC selection increasingly depends on tumour biology and prior treatment context. ctDNA-guided switching requires repeat testing. HRD signatures can guide treatment options in selected cancers. Molecular tumour boards need usable, interpretable reports.
This is why comprehensive genomic profiling should be treated as infrastructure, not luxury. The test itself is only one part of the pathway. The system also needs tissue handling, assay quality, turnaround standards, reporting formats, clinician interpretation, reimbursement and a way to connect results to approved therapies or clinical trials.
For IPM, this is the central access point: precision oncology is only as real as the diagnostic pathway that identifies eligible patients.
